Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orexin
Biotech
Alkermes eyes orexin ADHD drug as potential ‘company changer’
Alkermes is vying to be the first to push orexin agonists beyond sleep disorders and into broader patient populations like ADHD and fatigue.
Darren Incorvaia
Sep 21, 2026 7:00am
The GLP-like race to keep us awake and make billions doing it
Aug 31, 2026 11:24am
C4X sells substance disorder drug rights to Indivior for $20M
Aug 1, 2023 7:49am
Sosei spins out 2 CNS companies with help from Medicxi
Feb 4, 2019 10:23am
U.K.'s C4XD leaps on $294M addiction deal with Indivior
Mar 29, 2018 9:26am
